Medicare Coverage For New FDA-Approved Alzheimer’s Treatment, Leqembi: Groundbreaking Progress In Healthcare!
Introduction On Thursday, the U.S. Food and Drug Administration (FDA) achieved a significant milestone in Alzheimer’s treatment. It granted full approval to the Alzheimer’s treatment drug Leqembi, a collaborative product of Biogen BIIB and Eisai Co. Ltd. ESALF. This groundbreaking move provides assurance for Medicare reimbursement for the first-ever drug confirmed to slow down the […]